MHC class I-independent activation of virtual memory CD8 T cells induced by chemotherapeutic agent-treated cancer cells
Authors:
- 19 May 2020
- journal article
- research article
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 18 (3) , 723-734
Abstract
Cancer cells can evade immune recognition by losing major histocompatibility complex (MHC) class I. Hence, MHC class I-negative cancers represent the most challenging cancers to treat. Chemotherapeutic drugs not only directly kill tumors but also modulate the tumor immune microenvironment. However, it remains unknown whether chemotherapy-treated cancer cells can activate CD8 T cells independent of tumor-derived MHC class I and whether such MHC class I-independent CD8 T-cell activation can be exploited for cancer immunotherapy. Here, we showed that chemotherapy-treated cancer cells directly activated CD8 T cells in an MHC class I-independent manner and that these activated CD8 T cells exhibit virtual memory (VM) phenotypes. Consistently, in vivo chemotherapeutic treatment preferentially increased tumor-infiltrating VM CD8 T cells. Mechanistically, MHC class I-independent activation of CD8 T cells requires cell–cell contact and activation of the PI3K pathway. VM CD8 T cells contribute to a superior therapeutic effect on MHC class I-deficient tumors. Using humanized mouse models or primary human CD8 T cells, we also demonstrated that chemotherapy-treated human lymphomas activated VM CD8 T cells independent of tumor-derived MHC class I. In conclusion, CD8 T cells can be directly activated in an MHC class I-independent manner by chemotherapy-treated cancers, and these activated CD8 T cells may be exploited for developing new strategies to treat MHC class I-deficient cancers.Keywords
Funding Information
- Cancer League of Colorado
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R21-AI110777, R21-AI133110)
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA166325, R21-CA184707, R01-CA229174)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- American Association of Immunologists (Careers in Immunology Fellowship)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (F31DE027854)
- American Cancer Society (ACS IRG #16-184-56)
This publication has 57 references indexed in Scilit:
- Derivation and Maintenance of Virtual Memory CD8 T CellsThe Journal of Immunology, 2012
- Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell LymphomaCancer Cell, 2011
- Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2nullIl2rγnull mouse model: A multivariable optimization approachClinical Immunology, 2011
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- Alternative memory in the CD8 T cell lineageTrends in Immunology, 2011
- Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancerGut, 2010
- “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapyInternational Journal of Cancer, 2010
- The antigen-specific CD8+ T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansionJournal of Experimental Medicine, 2009
- HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's LymphomaJournal of Clinical Oncology, 2007
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002